The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.
21/10/2023
Session: ESMO Colloquium supported by Eisai Europe Ltd.
Optimising outcomes for patients with advanced renal cancer
- Welcome and introduction
Toni Choueiri - Current and emerging clinicopathologic and molecular prognostic schemes for patients with advanced renal cell carcinoma
Viktor Gruenwald - State-of-the-art combination therapies for patients with advanced RCC
Laurence Albiges - Do all patients need combination therapy? De-escalation and patient selection
Thomas Powles - Research insights in enhancing treatment efficacy: Escalation, sequencing and prediction
Toni Choueiri - Q&A and discussion
Toni Choueiri - Concluding remarks
Thomas Powles
22/10/2023
ESMO Colloquium supported by Eli Lilly and Company
Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer
- Welcome and introduction
Noemi Reguart Aransay - The importance of next-generation sequencing (NGS) testing in non-small cell lung cancer: Science, implementation and timing
Albrecht Stenzinger - The availability of molecular testing in Europe and its implications for state-of-the-art care for patients with lung cancer
Arnaud Bayle - Targeting molecular aberrations beyond EGFR, ALK: Clinical evidence for efficacy and ongoing research
Jürgen Wolf - Q&A and discussion
Noemi Reguart Aransay - Concluding remarks
Jürgen Wolf
ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca
The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC
- Welcome and introduction
Enriqueta Felip - Emerging data on the role of ADCs in the clinical care pathways for advanced NSCLC patients
Pasi Jänne - Improving the safety profiles of ADCs: Early detection and optimal management of toxicities
Maurice Pérol - Antibody-drug conjugates: Novel combinations with precision therapeutics and the quest for biomarkers
Anne-Marie Dingemans - Q&A and discussion
Enriqueta Felip - Concluding remarks
Pasi Jänne